Momenta Phama (MNTA) Misses Q3 EPS by 8c, Revenues Miss

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. RNG
2. DECK
3. WDC
4. BMY
5. BYD
6. SPOT
7. WCN
8. NDAQ
9. TSCO
10. BE

Go back to Momenta Phama (MNTA) Misses Q3 EPS by 8c, Revenues Miss

Momenta Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update

November 7, 2018 6:00 AM EST

CAMBRIDGE, Mass., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA) today reported its financial results for the third quarter ended September 30, 2018 and provided a corporate update.

We recently highlighted our pipeline of novel drug candidates for immune-mediated disorders at our recent R&D Day and, as we look to early 2019, we plan to have two Phase 2 trials of M281 initiated in gMG and HDFN and one Phase 1/2 trial of M254 initiated in ITP, said Craig A. Wheeler, President and Chief Executive Officer of Momenta Pharmaceuticals. To complement the... More